Syncona (SYNC) says that its portfolio company, Spur Therapeutics (Spur) has announced positive new data from its Phase I/II GALILEO-1 study of FLT201, its novel gene therapy candidate, in Gaucher disease at the 21st Annual WORLDSymposium in San Diego, CA, USA. The clinical trial In Spur’s trial, six patients have been treated in GALILEO-1 with … Continue reading Syncona’s Spur announces positive data for Phase I/II in Gaucher disease